These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 8300137)
21. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line. Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862 [TBL] [Abstract][Full Text] [Related]
22. Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies. Hirata Y; Taga T; Hibi M; Nakano N; Hirano T; Kishimoto T J Immunol; 1989 Nov; 143(9):2900-6. PubMed ID: 2681418 [TBL] [Abstract][Full Text] [Related]
23. Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Jernberg-Wiklund H; Pettersson M; Carlsson M; Nilsson K Leukemia; 1992 Apr; 6(4):310-8. PubMed ID: 1588793 [TBL] [Abstract][Full Text] [Related]
24. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Burger R; Neipel F; Fleckenstein B; Savino R; Ciliberto G; Kalden JR; Gramatzki M Blood; 1998 Mar; 91(6):1858-63. PubMed ID: 9490667 [TBL] [Abstract][Full Text] [Related]
25. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. Sidell N; Taga T; Hirano T; Kishimoto T; Saxon A J Immunol; 1991 Jun; 146(11):3809-14. PubMed ID: 2033252 [TBL] [Abstract][Full Text] [Related]
26. Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA. Okuno Y; Takahashi T; Suzuki A; Fukumoto M; Nakamura K; Fukui H; Koishihara Y; Ohsugi Y; Imura H Exp Hematol; 1992 May; 20(4):395-400. PubMed ID: 1568457 [TBL] [Abstract][Full Text] [Related]
27. Immunoassay for functional human soluble interleukin-6 receptor in plasma based on ligand/receptor interactions. Montero-Julian FA; Liautard J; Flavetta S; Romagné F; Gaillard JP; Brochier J; Klein B; Brailly H J Immunol Methods; 1994 Feb; 169(1):111-21. PubMed ID: 8133069 [TBL] [Abstract][Full Text] [Related]
28. Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization. Suthaus J; Adam N; Grötzinger J; Scheller J; Rose-John S Eur J Cell Biol; 2011; 90(6-7):495-504. PubMed ID: 21176991 [TBL] [Abstract][Full Text] [Related]
29. Soluble interleukin-6 receptor is released from receptor-bearing cell lines in vitro. Nakajima T; Yamamoto S; Cheng M; Yasukawa K; Hirano T; Kishimoto T; Tokunaga T; Honda M Jpn J Cancer Res; 1992 Apr; 83(4):373-8. PubMed ID: 1506271 [TBL] [Abstract][Full Text] [Related]
30. Interferon-alpha down-regulates the interleukin-6 receptor in a human multiple myeloma cell line, U266. Anthes JC; Zhan Z; Gilchrest H; Egan RW; Siegel MI; Billah MM Biochem J; 1995 Jul; 309 ( Pt 1)(Pt 1):175-80. PubMed ID: 7619053 [TBL] [Abstract][Full Text] [Related]
31. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Shima Y; Nishimoto N; Ogata A; Fujii Y; Yoshizaki K; Kishimoto T Blood; 1995 Feb; 85(3):757-64. PubMed ID: 7530506 [TBL] [Abstract][Full Text] [Related]
32. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells. Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270 [TBL] [Abstract][Full Text] [Related]
33. Introduction of the human interleukin-6 (IL-6) receptor in murine IL-3-dependent hematopoietic cells restores responsiveness to IL-6. Touw I; van Gurp R; Schipper P; van Agthoven T; Löwenberg B Blood; 1992 Jun; 79(11):2867-72. PubMed ID: 1586734 [TBL] [Abstract][Full Text] [Related]
34. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. Goto H; Shimazaki C; Tatsumi T; Yamagata N; Fujita N; Tsuchiya M; Koishihara Y; Ohsugi Y; Nakagawa M Leukemia; 1995 Apr; 9(4):711-8. PubMed ID: 7723407 [TBL] [Abstract][Full Text] [Related]
35. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells. Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863 [TBL] [Abstract][Full Text] [Related]
36. Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody. Kunikata T; Torigoe K; Ushio S; Okura T; Ushio C; Yamauchi H; Ikeda M; Ikegami H; Kurimoto M Cell Immunol; 1998 Nov; 189(2):135-43. PubMed ID: 9790727 [TBL] [Abstract][Full Text] [Related]
38. Expression and production of interleukin 10 in human myeloma cell lines. Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Yawata Y; Ueki A Br J Haematol; 2000 Dec; 111(3):835-42. PubMed ID: 11122145 [TBL] [Abstract][Full Text] [Related]
39. Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding. Hammacher A; Ward LD; Weinstock J; Treutlein H; Yasukawa K; Simpson RJ Protein Sci; 1994 Dec; 3(12):2280-93. PubMed ID: 7538847 [TBL] [Abstract][Full Text] [Related]
40. All-trans retinoic acid modulates Fas antigen expression and affects cell proliferation and apoptosis in combination with anti-Fas monoclonal antibody in the human myeloma cell line, U266B1. Okamura T; Masuda M; Arai Y; Ishida C; Shudou K; Mizoguchi H Exp Hematol; 1998 Jun; 26(6):501-6. PubMed ID: 9620283 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]